|

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

RECRUITINGPhase 4Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh
Actively Recruiting
PhasePhase 4
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
Started2026-01-01
Est. completion2029-01-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07322237

Summary

1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN. The drug has been found to be useful in large trials on heart failure with preserved ejection fraction in the general population with improvement in MASLD progression, with improvement in body weight and hepatic steatosis but no change in liver fibrosis. 2. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the development and progression of heart failure in patients with type 2 diabetes and in those with heart failure and a reduced and preserved ejection fraction. In patients with cirrhosis safety of empagliflozin in a dose of 10 mg has been demonstrated. 3. Prevention of decompensation related events in cirrhosis is the key endpoint of any liver-directed therapy as the median survival in the compensated state exceeds 10 years but median survival in the decompensated state approximates 1.5 years. Previous data has demonstrated the risk of hepatic decompensation acute kidney injury and poor survival in patients with cirrhosis and heart failure with preserved ejection fraction (HFpEF) i.e. LVDD a large subset of whom meet criteria for CCM.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion criteria

* Age range of 18-65 years
* Cirrhosis as diagnosed by histology or clinical laboratory and USG findings
* LVDD (with EF\>50%) on 2D echocardiography with TDI
* Written informed consent.

Exclusion criteria

* Age \>65 years
* Serum Creatinine\>2 mg/dl
* History of urinary tract /genital infections in last 3 months
* Patient on treatment with statin (one month before the study)
* Advanced Cirrhosis (MELD\>20)
* Coronary artery disease
* Sick sinus syndrome/ Pacemaker valvular heart disease
* Cardiac rhythm disorder Peripartum cardiomyopathy
* Portopulmonary hypertension/ hepatopulmonary syndrome
* Transjugular intrahepatic porto systemic shunt (TIPS) insertion
* Hepatocellular carcinoma
* Pregnancy or lactation
* Patients with HIV or retroviral therapy
* Anemia Hb \< 8gm/dl in females and \< 9 gm/dl in males
* Acute variceal bleeding in last 6months.

Conditions5

Cardiometabolic Risk FactorsCirrhosisCirrhotic CardiomyopathyEmpagliflozinHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.